Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page updates its software version from v3.6.3 to v3.6.4. This indicates a routine update that likely includes minor fixes or enhancements without changing the displayed study information.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision identifier was updated from v3.6.2 to v3.6.3. This indicates a minor update to the page (likely cosmetic or backend fixes) with no changes to the study information.SummaryDifference0.1%

- Check38 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2 on the page, indicating a software version update for ClinicalTrials.gov. It reflects backend or UI maintenance and does not change the study details, eligibility criteria, or participant information presented on the page.SummaryDifference0.1%

- Check53 days agoChange DetectedThe study page now states that no participants are being sought, clarifying that recruitment is closed for this trial.SummaryDifference0.4%

- Check60 days agoChange DetectedRevision: v3.5.5 was added to the page, replacing the previous revision tag and signaling a new release of the study record. This metadata update does not modify the study details or eligibility information.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the previous Revision: v3.5.3. This indicates a new version of the page/document has been released.SummaryDifference0.1%

Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.